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Environmental Approaches to the Prevention 
of Obesity
The NIEHS, along with the National Institute of
Diabetes and Digestive and Kidney Diseases, the
National Heart, Lung, and Blood Institute, the
National Center for Minority Health and Health
Disparities, the Office of Behavioral and Social
Sciences Research, the Office of Research on Women’s
Health, the Office of Disease Prevention, and the
Centers for Disease Control and Prevention, invites
applications to study promising interventions that
would target environmental factors that contribute to
inappropriate weight gain in children, adolescents, and
adults. Investigators applying to this RFA should pro-
pose to collaborate with organizations/institutions such
as schools, supermarkets, restaurants, religious organi-
zations, recreation facilities, industry, governmental,
public health, community groups, and work sites to
develop approaches that, if successful, could potentially
be translated into larger-scale interventions.
This RFA responds to the need for systematic
studies of environmental approaches to the preven-
tion of obesity. Although many environmental fac-
tors have been cited as contributing to obesity, there
have been few controlled studies showing that
changes in these factors will prevent weight gain. For
the purposes of this RFA, environmental interven-
tions are those that attempt to modify the external
surroundings with a goal of effecting behavioral
changes such as improvement in diet, increased phys-
ical activity, and/or decreased sedentary behaviors.
The goal of such interventions is to prevent inappro-
priate weight gain without exclusive reliance on an
individual’s knowledge or motivation. 
Behavioral and/or educational interventions (for
example, self-monitoring, motivational interviewing,
skills training) may be included in combination with
environmental changes; however, the primary focus of
the application should be on environmental modifica-
tion. For the purposes of this RFA, prevention of obe-
sity includes the primary prevention of overweight
and/or obesity, the prevention of additional weight
gain or increase in body fat in those already over-
weight and/or obese, and prevention of weight regain
following weight loss. However, studies of weight
management programs or use of medications or
dietary supplements to prevent weight gain are not
appropriate. Applications should address the content
of the intervention (e.g., relative focus on aspects of
diet, physical activity, sedentary behaviors, combina-
tions of these, or other factors), the setting of the
intervention (e.g., in a health care setting, work site,
community center, neighborhood, recreation facility,
home, school), and the method of intervention deliv-
ery (e.g., individual, family, group, community).
Applications targeting groups or populations at
high risk for developing obesity are encouraged. Novel
or innovative aspects of study design and the rationale
for their use should be highlighted.
The examples listed below are illustrative, and are
not meant to comprise an exhaustive list. It is expected
that additional important strategies and topics will be
identified by investigators who respond to this RFA.
Theory-based interventions are encouraged; however,
due to the need to explore innovative approaches,
“experience-based” interventions not based on formal
theory and other less well-developed concepts will be
considered if they are well justified. Applications for
full-scale studies should provide evidence from pilot
data supporting the intervention.
Examples of types of studies include but are not
limited to 1) studies to determine the impact of
changes in food advertising, food promotion, or
packaging on encouraging more healthful food choic-
es; 2) studies on the impact of economic factors, such
as pricing, on food choice or physical activity; 3)
studies that compare the effectiveness of innovative
environmental changes with individual behavior
therapy for prevention of weight gain; 4) studies on
the efficacy of establishing or reinforcing policies for
environments supportive of physically active and/or
healthful dietary lifestyles; 5) studies evaluating the
influence of neighborhood characteristics on levels of
physical activity and nutrition (for example, available
venues for safe indoor/outdoor exercise and accessi-
bility of fresh produce and other health-promoting
foods); 6) studies to implement culturally appropriate
interventions in collaboration with community-based
organizations to enhance physical activity and
improve nutrition; 7) studies examining sex and gen-
der differences in response to environmental inter-
ventions to prevent obesity; and 8) studies to evaluate
the impact of environmental interventions to prevent
obesity in underserved populations, including racial
and ethnic minority populations and rural women.
This RFA will use the NIH research project grant
(R01) award mechanism. Pilot studies, also using the
R01 mechanism, will be considered if limited in scope
and duration. The total requested project period for an
application submitted in response to this RFA may not
exceed 5 years for full-scale clinical trials and 3 years for
pilot studies.
For the initial year of funding, approximately
$4 million will be committed to fund applications sub-
mitted in response to this RFA. It is anticipated that
5–12 awards will be made, contingent upon the avail-
ability of funds for this purpose. However, this fund-
ing level is dependent upon the receipt of a sufficient
number of applications of high scientific merit. 
The deadline for letters of intent is 14 February
2002, with final applications due 14 March 2002.
More information on this RFA is available online at
http://grants.nih.gov/grants/guide/rfa-files/
RFA-DK-02-021.html. The PHS 398 research grant
application instructions and forms (rev. 5/2001) at
http://grants.nih.gov/grants/funding/phs398/phs398.
html must be used in applying for these grants.
Contact: Robert Kuczmarski, Obesity Prevention
and Treatment Program, Division of Digestive
Diseases and Nutrition, NIDDK, 6707 Democracy
Boulevard, Room 673, MSC 5450, Bethesda, MD
20892-5450 USA, 301-451-8354, fax: 310-480-8300,
e-mail: rk191r@nih.gov. Reference: RFA No. RFA-
DK-02-02
Studies of the Ethical, Legal, and Social
Implications (ELSI) of Human Genetic Variation
Research for Individuals and Diverse Racial and
Ethnic Groups
While the ultimate goal of studies aimed at relating
human genetic variation to disease risk is the improve-
ment of human health, concerns have been raised that
the findings of some genetic variation research may be
misunderstood. Concerns have also been raised that
such findings, if interpreted incorrectly and misused,
will exacerbate rather than ameliorate existing health
disparities among racial, ethnic, and socioeconomic
groups. The National Human Genome Research
Institute (NHGRI), through its Ethical, Legal, and
Social Implications (ELSI) Research Program, proposes
a new initiative to encourage additional ELSI research
on genetic variation research for both individuals and
diverse population groups. Examples of the types of
topics that would be appropriate for applications sub-
mitted under this initiative include but are not limited
to the following: 
1) How will individuals understand and use
genetic information that suggests the possibility of a
meaningful association between their genotype and
increased or decreased risk for a particular common,
complex disorder (or between their genotype and
increased or decreased responsiveness to a particular
medication or susceptibility to a potentially hazardous
environmental substance)? How will genetic informa-
tion that suggests the possibility of differences in fre-
quencies among groups of the genetic variants that
contribute to these traits be understood and used?
2) How will genetic information that suggests the
possibility of group differences in the prevalence of a
genotype associated with increased or decreased risk for
a particular common, complex disorder (or increased
or decreased responsiveness to a particular medication
or susceptibility to a potentially hazardous environ-
mental substance) be understood and used by health
professionals? How will it be understood and used by
various other societal decision makers (e.g., insurance
companies, pharmaceutical companies, employers,
health care policy makers, environmental policy mak-
ers, educational institutions, courts, adoption agencies,
the military)? How will this information differentially
affect individual decision making over the life course
(e.g., insurance, retirement age, savings)? How will this
information affect public and institutional policy for
the aged (e.g., Social Security, Medicare, retirement
benefits) or for individuals with disabilities? What
long-term effect, if any, will the use of this information
have on health disparities among groups?
3) In reporting the results of human genetic
variation research, how do investigators assign causal-
ity when a particular disorder is associated with both
genetic and nongenetic (environmental, behavioral,
social) risk factors? How do the media assign causali-
ty when reporting on such studies? What are the ethi-
cal obligations of investigators when they report the
findings of disease–gene association research involv-
ing common, complex disorders? What are the ethi-
cal obligations of the media when they report on
such studies?
4) How do investigators define and describe the
groups with whom they conduct human genetic varia-
tion research? How do the media describe those groups
when reporting on such studies? What are the ethical
obligations of investigators when they define and
describe the groups with whom they conduct genetic
variation research? What are the ethical obligations of
the media when they report on such studies?
5) What new problems arise for individuals and
groups when genetic variation data are incorporated
into social survey research? How will individuals and
groups perceive the risks and benefits of participating
in these surveys? How can these surveys be used to
study the factors motivating participation?
6) How are the statements that “all human beings
are 99.9% genetically the same” and “there is no bio-
logical basis for precise racial categorizations” under-
stood by individuals who self-identify as members of
particular racial, ethnic, or socioeconomic groups?
How do such statements affect how groups define
themselves or are defined by others? What is the
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impact of such statements on individual conceptions of
self and group identity?
This RFA will use the NIH regular research pro-
ject grant (R01) and small research project grant (R03)
award mechanisms. The PHS 398 research grant appli-
cation instructions and forms (rev. 5/2001) at
http://grants.nih.gov/grants/funding/phs398/
phs398.html must be used in applying for these grants.
The deadline for letters of intent is 1 March 2002,
with final applications due 10 July 2002. More infor-
mation is available online at http://grants.nih.
gov/grants/guide/rfa-files/RFA-HG-02-003.html. 
Contact: Rudy Pozzatti, Office of Scientific
Review, NHGRI, 31 Center Drive, Room B2B37,
Bethesda, MD 20892-2033 USA, 301-402-0838, fax:
301-435-1580, e-mail: rp7s@nih.gov. Reference: RFA
No. RFA-HG-02-003
Cancer Prevention, Control, Behavioral, and
Population Sciences Career Development Award
The purpose of the Cancer Prevention, Control,
Behavioral, and Population Sciences Career Develop-
ment Award is to support the career development of
investigators who wish to focus their research endeav-
ors on cancer prevention, control, and behavioral and
population sciences. This mechanism provides support
for 3–5 years of specialized didactic study and men-
tored research for individuals with a health professional
or science doctoral degree who are not fully established
investigators. Examples of relevant disciplines for this
PA include any aspect of human cancer prevention
(modifiable risk factors, new animal models and
extrapolation of these models to human cancer, genetic
predisposition to cancer and detection of precursor
lesions, chemoprevention trials in human populations,
and behavioral research and behavioral intervention tri-
als in cancer prevention), epidemiology (biochemical,
genetic, and molecular), biostatistics, human cancer
genetics, clinical oncology, human nutrition, behav-
ioral and social sciences, health promotion, health ser-
vices and health policy research, and medical decision
analysis, survivorship, and quality of life as they relate
to cancer.
The award provides support for up to five consec-
utive 12-month periods. A minimum of 75% effort
must be devoted to the program. The remaining 25%
can be divided among other clinical and teaching activ-
ities and coursework only if these activities are consis-
tent with the program goals. Both the didactic and
research phases of the award are expected to develop
necessary knowledge and research skills in scientific
areas relevant to the career goals of the candidate in
cancer prevention, cancer control, and behavioral and
population sciences research. Candidates lacking skills
in data management, statistics, epidemiology, study
design, clinical trial design, hypothesis development,
etc. can be provided the opportunity to participate in
courses designed to overcome these deficiencies.
The award provides a career development oppor-
tunity for 1) individuals already proficient in general
epidemiology, the behavioral sciences, or other relevant
disciplines, and 2) individuals already trained in cancer
epidemiology, etiology, prevention, control, and the
behavioral and population sciences to become fully
independent investigators. The scope of the
research/didactic training may extend from the devel-
opment and experimental testing of hypotheses,
through the stage of confirming results using defined
populations, to the development and demonstration of
technology as applied to epidemiology, cancer preven-
tion, cancer control, and the behavioral and population
sciences as they relate to cancer.
This PA will use the NIH K07 award mechanism.
The total project period for applications may not
exceed 5 years. Awards made for a 5-year project peri-
od, or recommended by peer review for a shorter pro-
ject period, are not renewable.
Applications are to be submitted on the grant
application form PHS 398 (rev. 5/2001), available
online at http://grants.nih.gov/grants/funding/
phs398/phs398.html, and should use the instructions
in Section IV of the application kit. The application
will be accepted at the standard application deadlines
for K-awards as indicated in the application kit. For
further assistance, call 301-435-0714 or e-mail
GrantsInfo@nih.gov. Further information on this PA
is available online at http://grants.nih.gov/grants/
guide/pa-files/PAR-01-135.html.
Contact: Brian Kimes, Cancer Training Branch,
National Cancer Institute, 6116 Executive Boulevard,
Suite 7001, MSC 8345, Bethesda, MD 20892-8346
USA, 301-496-8537, fax: 301-402-0181, e-mail:
bk34t@nih.gov. Reference: PAR No. PAR-01-135
Cooperative Planning Grant for Cancer Disparities
Research Partnership
The National Cancer Institute (NCI) invites coopera-
tive planning grant applications (using the U56 mecha-
nism) in an effort to strengthen the national cancer
program by developing models to reduce significant
negative consequences of cancer disparities seen in cer-
tain U.S. populations. This grant will support the plan-
ning, development, and conduct of radiation oncology
clinical research trials in institutions that care for a dis-
proportionate number of medically underserved, low
income, ethnic, and minority populations but have not
been traditionally involved in NCI-sponsored research.
The grant will also support the planning, development,
and implementation of nurturing partnerships between
applicant institutions and committed and experienced
institutions actively involved in NCI-sponsored cancer
research. All approaches to planning are encouraged, as
long as they address the following essential features: a
focus on cancer disparities, radiation oncology clinical
research, institutional commitment, organizational
capabilities, facilities, and interdisciplinary coordina-
tion and collaboration.
The four overall objectives and scope of this
RFA are to solicit cooperative planning grants that
would 1) build and stabilize independent and collab-
orative clinical research capabilities of institutions
providing radiation oncology care to populations
experiencing the negative consequences of cancer-
related health disparities; 2) increase the number of
clinical scientists engaged in radiation oncology
research by providing access to and participation in
clinical trials with the target populations; 3) improve
the effectiveness of the applicant institution and its
partner institution in developing and sustaining
activities focused on radiation oncology clinical
research trials and mortality and morbidity in cancer
among the target populations, continuing past the
life of this grant; and 4) establish priorities for and
initiate stable, long-term collaborations and partner-
ships that will strengthen competitive cancer
research, research training and career development,
education, and outreach capabilities at both the
applicant institution and the partner institution that
address problems and issues relevant to the dispro-
portionate cancer incidence and mortality.
The most significant components of a U56
Cancer Disparities Research Partnership application
are 1) a thorough description and implementation plan
of the proposed radiation oncology clinical trials
research effort that must address the negative conse-
quences of cancer disparities in the population served
with the inclusion of examples of pilot clinical trials
research projects, and 2) the articulation of the steps to
be taken with potential partner institutions during the
first year of the award to develop a comprehensive and
supportive partnership relationship and the subsequent
implementation of that plan over the remaining life of
the grant with the selected partner. The expectation is
that successful Cancer Disparities Research Partnership
projects will ultimately be competitively funded grants
(e.g., R03, R01, project on a P01, project on a P50).
The NCI is strongly committed to reducing can-
cer-related health disparities across the cancer control
continuum from prevention to end-of-life. The NCI
Strategic Plan to Reduce Health Disparities is available
online at http://www.cancer.gov/announcements/
healthdisp.html. The NCI supports research to under-
stand the complex causes of disparities in cancer risk,
incidence, and mortality, including socioeconomic,
cultural, environmental, institutional, behavioral, bio-
logic, and other contributing factors seen in the health
care delivery system. The overall goal is to understand
the causes of health disparities and to develop effective
interventions to eliminate these disparities that result in
significant negative outcomes. More research is needed
that specifically addresses these and other cancer dis-
parities if these trends are to be reduced and brought
into balance with the rest of the population. 
The NCI and the Radiation Research Program
(RRP) anticipate making up to three 5-year grant
awards in fiscal year 2002. The NCI/RRP plans to set
aside $2.1 million for the initial year’s funding, which
includes direct costs, costs for facilities and administra-
tion, and one-time capital equipment costs. Excluding
one-time capital costs expended in the first year, appli-
cants may request a budget for direct costs of up to an
average of $400,000 per year over the 5 years of the
grant. The total project period for applications submit-
ted in response to this RFA may not exceed 5 years.
The anticipated award date is 20 September 2002.
The deadline for letters of intent is 6 February
2002, with final applications due 13 March 2002.
Further information on this RFA is available online at
http://grants.nih.gov/grants/guide/rfa-files/
RFA-CA-02-002.html. 
Contact: Frank Govern, Radiation Oncology
Sciences Program, NCI, Executive Plaza North,
6015A, 6130 Executive Boulevard, MSC 7440,
Bethesda, MD 20892-7440 USA, 301-496-6111, fax:
301-480-5785, e-mail: governfr@mail.nih.gov;
Norman Coleman, Radiation Oncology Sciences
Program, NCI, DCTD, RRP, Executive Plaza North,
6015A, 6130 Executive Boulevard, MSC 7440,
Bethesda, MD 20892-7440 USA, 301-496-6111, fax:
301-480-5785, e-mail: ccoleman@mail.nih.gov.
Reference: RFA No. RFA-CA-02-002
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